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Abstract: While multiple testing procedures have been the focus of much
statistical research, an important facet of the problem is how to deal with
possible confounding. Procedures have been developed by authors in genetics
and statistics. In this chapter, we relate these proposals. We propose two new
multiple testing approaches within this framework. The first combines sensi-
tivity analysis methods with false discovery rate estimation procedures. The
second involves construction of shrinkage estimators that utilize the mixture
model for multiple testing. The procedures are illustrated with applications to
a gene expression profiling experiment in prostate cancer.
1. Introduction
In the study of complex diseases such as cancer, investigators have sought to impli-
cate candidate gene polymorphisms with disease. Candidate gene polymorphisms
have been typically identified in case-control studies, where their frequencies in
cases and controls are typically compared. Such studies are quite commonplace in
the scientific literature.
For this context, we focus on the problem of multiple testing. A useful quantity to
consider in multiple testing situations is the false discovery rate (FDR) (Benjamini
and Hochberg [2]). Sabatti et al. [24] and Abecasis et al. [1] have advocated its use
in genetic association studies. There has been a lot of work on statistical procedures
involving the false discovery rate, which we review in Section 2. While much work
has been done on multiple testing procedures, very little work to date has been
done on estimation for this setting.
Recently, Efron [11] has argued that these methods presume theoretical null dis-
tributions, which might be incorrect, and has instead argued for use of an empirical
null distribution. A parallel development of this problem has occurred in genetic
association studies (Cardon and Bell [7]), in which statistical geneticists look at
frequencies of alleles in affected (case) and unaffected (control) populations to de-
termine associations between genes and disease. Wright [36] argued that a variety
of population genetic forces, such as nonrandom mating and genetic drift, might
induce genetically similar subgroups within populations. This is referred to as pop-
ulation structure in the genetic literature. Proposals for addressing this problem
have been developed by Devlin and Roeder [10] and Rosenberg and Pritchard [23].
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In this article, we seek to unify these proposals in a framework for multiple
testing in which we adjust for confounding. The population structure that must
be accounted for in genetic association studies represents one type of confound-
ing. There has also been mention on the role of other confounders in differential
expression analyses for microarray data (Bhattacharya et al. [6] and Ghosh and
Chinnaiyan [17]). Confounding is a problem in that it biases the associations that
are observed in the data. In other words, because of confounding, under the null
hypothesis of no association, the usual test statistic does not have the correct mean.
The structure of this paper is as follows. In Section 2, we define the false dis-
covery rate and review the standard mixture model for multiple hypothesis testing
that has been used in the literature. We then slightly generalize the model to al-
low for confounding and then relate three proposals for multiple testing (Devlin
and Roeder [10], Pritchard and Rosenberg [23] and Efron [11]) to this model. We
then propose two analytical schemes for multiple testing in the presence of con-
founding. The first involves utilization of sensitivity analysis methods to adjust for
confounding (Lin et al. [19]), followed by q-value estimation (Storey [28]) or a false
discovery rate controlling procedure. This, along with the link to related shrinkage
estimation procedures (James and Stein [18], Sen and Saleh [26, 27] and George
[15]), is discussed in Section 3. In Section 4, we discuss estimation of association,
along with confidence intervals in the multiple testing situation in the presence of
confounding. We highlight the procedures with applications to a gene expression
data from a prostate cancer study in Section 5. Finally, we conclude with some
discussion in Section 6.
2. Data structures, background and preliminaries
Suppose there are g genes that we wish to make gene-specific hypotheses about.
We can cross-classify the corresponding g hypotheses into their true status (i.e. null
is true or alternative is true) and also based on whether or not we decide to reject
the null hypothesis. Such a table is given in Table 1.
The classical quantity that has been controlled in multiple testing problems has
been the familywise type I error rate (FWER). Based on Table 1, the FWER is
defined as P (V ≥ 1). By contrast, the definition of false discovery rate (FDR) as
put forward by Benjamini and Hochberg [2] is
FDR ≡ E
[
V
Q
|Q > 0
]
P (Q > 0).
The conditioning on the event [Q > 0] is needed because the fraction V/Q is not
well-defined when Q = 0. If all the null hypotheses are true (i.e., g0 = g), then
control of the false discovery also provides control of the familywise type I error
rate. In general, however, control of the two quantities are not equivalent, and the
control of the false discovery rate is less conservative than that of FWER.
Table 1
Outcomes of G tests of hypotheses
Accept Reject Total
True null U V G0
True alternative T S G1
W Q G
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FDR-related procedures fall into two classes: (1) methods that aim to control
FDR; (2) methods for direct estimation of FDR based on a fixed rejection region.
The first class of procedures has been proposed by many authors, such as Benjamini
and Hochberg [2], Benjamini and Liu [3], Benjamini and Yekutieli [4] and Sarkar
[25]. Efron et al. [12], Storey [28, 29] and Genovese and Wasserman [13], 2005 have
developed the second class of procedures. The two classes of methods have been
unified by Storey et al. [30] and Genovese and Wasserman (2005). The FDR is also
linked intimately to the q-value (Storey [28]), the smallest FDR at which a null
hypothesis can be rejected.
2.1. Mixture model framework for multiple testing
For false discovery rate estimation procedures, many authors have studied a mixture
model for multiple testing. To test each null hypothesis, let Tg denote the test
statistic for the gth gene. Define indicator variables H1, . . . , HG corresponding to
T1, . . . , TG, where Hi = 0 if the null hypothesis is true and Hi = 1 if the alternative
hypothesis is true. Assume that H1, . . . , HG are a random sample from a Bernoulli
distribution where P (Hi = 0) = pi0, i = 1, . . . , G. We define the densities f0 and f1
corresponding to Ti|Hi = 0 and Ti|Hi = 1, (i = 1, . . . ,m). The marginal density of
the test statistics T1, . . . , Tm is given by
(2.1) f(t) ≡ pi0f0(t) + (1− pi0)f1(t).
The mixture model framework represented in (2.1) has been used by several authors
to study the false discovery rate (e.g., Efron et al. [12], Storey [28] and Genovese
and Wasserman [14]). Given an estimate of pi0, methods for false discovery rate
estimation have been developed by several authors (Efron et al. [12] and Storey
[28]). There are several methods for estimating pi0 in the literature, most of which
are based on the defintion of pi0 as the derivative of the density of test statistics
corresponding to the null hypothesis evaluated at one. The latter definition can
be found in Storey and Tibshirani [31]; methods of estimation of pi0 can be found
in Storey [28], Pounds and Cheng [22] and Dalmasso et al. [8]. Intuitively, it is
estimated based on p-values that in a region close to one; the size of the region will
be inevitably linked to a bias-variance tradeoff regarding the estimate of pi0.
2.2. Adjustments for confounding
In model (2.1), authors have usually assumed f0 to be known. For example, if the
test statistics are p-values, then f0 has been assumed to be the pdf of a Uniform(0,1)
random variable. If the statistics are Wald-type statistics (e.g., two sample t-tests),
then f0 is usually taken to be a normal distribution with mean zero and variance
one.
There have been certain proposals in which authors attempted to use permuta-
tion methods to estimate f0 (e.g., Efron et al. [12]). This technique has been used
to account for correlation between the hypotheses, e.g. genes on a microarray hav-
ing correlation. Permutation is often carried out by interchanging labels between
independent samples. However, a crucial assumption of permutation method is that
under the null hypothesis, all assignments of class labels to samples are exchange-
able. In the presence of confounding, this assumption is no longer true. This is why
Efron [11] writes that “permutation methods do no automatically resolve the issue
of the theoretical versus the empirical null hypothesis.”
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To account for confounding, let us assume that under the null hypothesis, the ith
test statistic Ti has distribution f
C
0i(t), where the subscript C denotes confounding.
Assume that under the alternative hypothesis, the distribution is fC1i(t) for Ti,
i = 1, . . . , n. Then we have the following mixture model:
(2.2) Ti
ind
∼ pi0f
C
0i(t) + (1− pi0)f
C
1i(t).
Assume further that fC1i(t) does not depend on i. Suppose there were supplementary
test statistics U1, . . . , UK available for which it were known that the null hypothesis
was true. The framework of Devlin and Roeder [10] works in the following manner.
Using a population genetic model and the presence of population stratification,
they show that fC0i(t) will be relatively overdispersed compared to f0i(t), which they
assume not to depend on i. To be specific, fC0i(t) = σ
−1
i f0(t/σi).While there should
also be a mean shift (i.e. bias correction) in fC0 relative to f0, Devlin and Roeder
[10] argue that the overdispersion outweighs the bias; this has been supported by
other authors using simulation studies (Wacholder et al. [34]). Making a further
assumption that the scale parameter σi is constant across the genome so that it no
longer depends on i, Devlin and Roeder [10] use the statistics U1, . . . , UK to estimate
σ. Let the resulting estimator be denoted as σˆ; one can then use in σˆ−1f0(t/σˆ) as
the reference null hypothesis for multiple testing. Devlin and Roeder [10] argue
for the constant variance assumption across the genome using population genetic
arguments.
An alternative approach to adjusting for confounding was put forward by
Pritchard and Rosenberg [23]. They postulated the existence of a latent variable C
such that conditional on C = c,
(2.3) Ti|C = c
iid
∼ pi0f0(t) + (1− pi0)f1(t),
i.e. within subpopulations defined by C, the test statistics have the distribution
defined as in (2.1). In their method, what is needed are supplementary data that
can be used to define C for each individual. Just as in the genomic control method
of Devlin and Roeder [10], these are data on genes for which the null hypothesis is
known to be true. The approach of Pritchard and Rosenberg [23] is to infer sub-
population membership (C) using the supplementary data and then do standard
multiple testing within each subpopulation. Conditional on C (i.e., within subpopu-
lations defined by C), the theoretical null and alternative distributions can be used
for the multiple testing problem. For Pritchard and Rosenberg [23], they use the
supplemental data to infer subpopulation membership and then for those defined by
common values for the inferred cluster membership, they can perform the standard
multiple testing procedures.
The approach of Efron [11] involves the following model:
(2.4) Ti
iid
∼ pi0f
C
0 (t) + (1− pi0)f
C
1 (t).
Thus, the density of the test statistics corresponding to the null and alternative
hypotheses are left unspecified. No relationship between fC0 (t) to f0(t) is formulated,
making this approach more flexible than that of Devlin and Roeder [10]. In addition,
no supplemental data are required on known true null hypotheses, in contrast to
the Devlin and Roeder [10] and Pritchard and Rosenberg [23] proposals. To make
estimation in (2.4) feasible, Efron [11] makes a zero-matching assumption, namely
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that all statistics near zero come from the null hypothesis component and relates
f1 to f0 via an exponential tilt (Lindsey [20]).
In comparing the proposals, we find that both the method of Pritchard and
Rosenberg [23] and Devlin and Roeder [10] both require supplemental data, as well
as an assumption that the supplemental data are not associated with the phenotype
in any manner. By contrast, no supplemental data are needed for the method of
Efron [11]. However, a desirable feature of the first two proposals mentioned is that
they explicitly model the confounding in an easily interpretable way into the model.
The Efron approach is more algorithmic in nature, although he mentions confound-
ing as being one reason to prefer the empirical null relative to the theoretical null
hypothesis.
If we think of confounding as manifesting through a bias and variance adjust-
ment to the theoretical null distribution, then we find that the genomic control
method makes a variance adjustment to the theoretical null, while the approach of
Pritchard and Rosenberg [23] proposal makes an adjustment to both through the
latent variable C. The Efron [11] procedure also does the same without specifying
a probabilistic model for the confounding. The first approach we propose in this
paper is to postulate confounding in a manner analogous to Pritchard and Rosen-
berg [23]; however, the actual multiple testing procedures do not require additional
data, which makes it similar to the approach of Efron [11]. An important step in
application of the proposed methodology is the use of sensitivity analysis methods,
which are described next.
3. Sensitivity analysis and multiple testing methodologies
To incorporate confounding into the analysis, we will utilize the framework of Lin
et al. [19]. They cast sensitivity analysis into a regression modelling framework in
which the confounder was treated as an unobserved covariate. While they focused
primarily on binary and time-to-event outcomes, the data we consider in Section 5
involves a continuous response. Also, we have the issue of multiple testing.
3.1. Continuous response
We observe the data (Xi, Di), i = 1, . . . ,m, where Xi is the n-dimensional covari-
ate vector and Di the binary phenotype for the ith individual. We formulate the
following regression model relating X and D:
(3.1) E(Xki|Di, U) = β0k + β1kDi + γCi,
where (β0, β1) are regression coefficients, C represents the confounder and γ is the
associated regression coefficient. Note that we assume no interaction between Ci
and Di in (3.1). Since C is not observed, we fit the reduced model:
(3.2) E(Xki|Di) = β
∗
0k + β
∗
1kDi.
We want to determine the relationship between β1 and β
∗
1 . Note that integrating
(3.1) with respect to the conditional distribution of C given D implies the following
model:
(3.3) E[Xik|Di] = β0k + β1kDi + γE[Ci|Di].
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We now assume C|D to be normal with mean µD and variance one. For this situa-
tion, plugging in the definition and equating regression coefficients for Di in (3.3)
and (3.2) yields
(3.4) β1k = β
∗
1k − γ(µ1 − µ0).
Thus, after the user specifies γ and the difference (µ1 − µ0), the estimate of β1k,
βˆ1k, can be found quite easily by direct computation into (3.4) Since the inputs
are constants, this has no impact on the standard errors of β1k. One can then
use βˆ1k/SˆE(βˆ
∗
1k) as the Wald statistic which when compared to a standard normal
distribution yields a p-value. Again, the standard errors are unaffected by the sensi-
tivity analysis parameters, and we can obtain p-values based on the Wald statistic.
3.2. Q-value/FDR adjustment for multiple testing
Based on the p-values calculated in the previous section, one can construct
hypothesis-specific q-values (Storey and Tibshirani [31]). Q-values are defined to
be the smallest FDR at which a test of hypothesis is significant, analogous to the
p-value being the smallest level of significance at which a test of hypothesis is
deemed to be significant. Here is the q-value construction algorithm:
1. Order the G p-values as p(1) ≤ p(2) ≤ · · · ≤ p(G).
2. Construct a grid of L λ values, λ1, . . . , λL and calculate
pˆi0(λl) =
#{pj > λl}
G(1 − λl)
,
l = 1, . . . , L.
3. Fit a cubic smoothing spline to the values {λl, pˆi0(λl)}, l = 1, . . . , L.
4. Estimate pi0 by the interpolated value at λ = 1.
5. For the gene with the largest p-value the q-value is given by
q(p(G)) = min
t≥p(G)
pˆi0Gt
#{pj ≤ t}
= pˆi0p(G),
and for i = G − 1, G − 2, . . . , 1, q(p(i)) = min(pˆi0Gp(i)/i, pˆ(i+1)). This guar-
antees that the q-values will be monotonically increasing as a function of
p-values.
An alternative approach is to use the p-values in the Benjamini-Hochberg [2]
procedure for controlling the false discovery rate:
(a) Let p(1) ≤ p(2) ≤ · · · ≤ p(G) denote the ordered, observed p-values.
(b) Find kˆ = max{1 ≤ k ≤ G : p(k) ≤ αk/G}.
(c) If kˆ exists, then reject null hypotheses p(1) ≤ · · · ≤ p(kˆ). Otherwise, reject
nothing.
The major adjustment in these procedures is that we are accounting for potential
adjustment of confounding, which impacts the p-values that get used in the multiple
testing procedures.
Note that while we have used q-values to adjust for the multiple testing problem,
the p-values can be input into any single-step algorithm for multiple testing. If we
wished to control the familywise type I error level instead, we could use any of the
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procedures from Westfall and Young (1993) or some of the more recent methods
from Van der Laan and Dudoit and colleagues (Van der Laan et al. [32, 33]).
One thing to note about the sensitivity analysis method described in Section 3.1
and is that it is effectively making an mean-shift adjustment to the theoretical null
distribution. In particular, the standard errors of the estimators are not affected by
the sensitivity analysis method of Lin et al. [19]. The multiple testing model that
adjusts for confounding assumed here, in the notation of Section 2, is the following:
(3.5) Ti|Θ
iid
∼ pi0f0(t−Θ) + (1− pi0)f1(t),
where Θ denotes the sensitivity analysis inputs and are fixed constants specified
by the user. One advantage of such a model for confounding is that it requires
minimal user input and is easy to implement. A second advantage is that what are
affected in this procedure is the estimate of pi0 and the actual q-values themselves.
In settings where investigators are interested in the selection of hypotheses, these
quantities might be all that is of interest.
In comparing this mixture model with (2.2) and (2.3), we find that the sensitivity
analysis approach models confounding as a shift in the mean for the confounding
null density relative to the theoretical null density. We allow for nonconstant vari-
ance across the genome, in contrast to the approach of Devlin and Roeder [10]. In
addition, unlike Devlin and Roeder [10], we model the bias due to confounding.
By comparison, the Pritchard and Rosenberg [23] and Efron [11] approaches would
allow for both a mean and variance adjustment for the null hypothesis density.
It appears that combining the approach here with that of genomic control should
provide an answer that is closer to the Pritchard and Rosenberg [23] proposal, if
supplemental data were available.
3.3. Shrinkage estimation for the q-value
We now heuristically describe an argument, given in more detail in Ghosh [16], that
shows how the q-value can be motivated as a shrinkage estimator in the multiple
testing problem. Consider model (2.1) again, where the test statistics are the p-
values. Then one could construct shrinkage estimators of the p-values where they
are shrunk towards the components of the mixture model defined by (2.1). If we
assume that the density of the null hypothesis is a point mass at one and that of
the alternative is zero, then it is shown in Ghosh [16] that a shrinkage estimator
of the p-value in this problem is lower bounded by the q-value. Thus, the q-value
approach advocated by Storey [28] enjoys a nice shrinkage property. However, the
definition of the q-value given by Storey [28] is appropriate to the situation of 0/1
loss (misclassification error). The shrinkage estimation procedure by Ghosh [16]
could generalize easily to other loss functions, which might be more appropriate in
other scientific contexts.
4. Estimators of association in the presence of confounding
A limitation of all these approaches is that they do not produce multiple-testing
adjusted estimates of association or confidence intervals. We now discuss the prob-
lem of how to estimate association measures in the multiple testing problem in the
presence of confounding. While the multiple testing problem has been considered
quite intensively in the statistical literature, that of estimating associations has not.
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This was pointed out recently by Prentice and Qi [21] in a genomewide study ex-
ample. Our approach is based on the idea that we can use (2.1) to define estimation
targets under the null and alternative hypotheses. One then can define Empirical
Bayes estimators that shrink the observed test statistic towards each target with
appropriate mixing weights.
For estimation, James-Stein (James and Stein [18]) estimators are used. We now
construct the double shrinkage estimators using the test statistic model (2.1) where
F = pi0F0+(1−pi0)F1. To do this, we utilize the density estimation method proposed
by Efron [11]. Note from (2.1) that we have
pi1f1(t) = f(t)− pi0f0(t).
We can estimate f(t) by applying density estimation methods to T1, . . . , TG. For
estimation of pi0f0(t), the zero assumption in Efron [11] is utilized. What this means
is that most test statistics with a value near zero comes from the null distribution
component. The assumption, combined with a normal-based moments matching
technique and density estimation procedures as described in Efron [11], allows one
to obtain an estimate of pi0 and f0(t). Given them, we then obtain an estimate of
pi1 and f1(t) by simple subtraction. Based on the estimates of f0(t), f1(t) and pi0,
we can estimate T JS1 , . . . , T
JS
n by
(4.1) Tˆ JSi = pˆi0(Ti)Tˆ
JS
0i + {1− pˆi0(Ti)}Tˆ
JS
0i ,
where
Tˆ JS0i = Ti −
[
1 ∧
G− 2∑G
i=1(Ti − µˆ0)
2
]
(Ti − µˆ0),
Tˆ JS1i = Ti −
[
1 ∧
G− 2∑G
i=1(Ti − µˆ1)
2
]
(Ti − µˆ1),
pˆik(t) =
pˆikfˆk(t)
pˆi0fˆ0(t) + (1− pˆi0)fˆ1(t)
,
µˆ0 =
∫
tdFˆ0(t) and µˆ1 =
∫
tdFˆ1(t).
Before discussing the issue of confidence intervals, note that we are using the
model framework of Efron [11] to deal with confounding, i.e., model (2.4). As men-
tioned before, estimation in this model requires no supplemental data on known
null hypotheses.
Along with estimators of the parameters that adjust for multiple testing, it is
useful to have confidence intervals that also account for the multiple testing phe-
nomenon. To calculate the confidence intervals, we will use the following simulation-
based algorithm:
1. Estimate pi0, f0 and f1 using the algorithm above.
2. Construct the double shrinkage estimators of µ1, . . . , µG, Tˆ
JS
1 , . . . , Tˆ
JS
G .
3. Sample with replacement G observations µ∗1, . . . , µ
∗
G from the estimated den-
sity pˆi0fˆ0(t) + (1− pˆi0)fˆ1(t) and generate T
∗
1,1, . . . , T
∗
G,1, where T
∗
i,1 ∼ N(Tˆ
JS
i ,
1 + σˆ2∗), where σˆ
2
∗ is the empirical variance of the µ
∗’s sampled in Step 2.
4. Repeat Step 3 B times. Use the empirical distribution of T ∗i,1, . . . , T
∗
i,B to
calculate confidence intervals for µi, i = 1, . . . , G.
5. Multiply by the gene-specific standard deviations to get confidence intervals
on the scale of the parameter.
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Based on the bootstrap distributions, we can construct confidence intervals for each
of the components of µ ≡ (µ1, . . . , µG). We have chosen to use equal tail confidence
intervals, e.g. a 95% confidence interval would be based on the 2.5th and 97.5th
percentiles of the empirical distribution of T ∗i .
5. Numerical example: Microarray profiling study in prostate cancer
We now illustrate the proposed methodologies using two genomic studies. The
first comes from prostate cancer gene expression profiling experiment reported in
Varambally et al. [35]. The investigators used cDNA microarrays containing 9984
genes to profile tissue samples from various stages of prostate cancer (normal ad-
jacent prostate, benign prostatic hyperplasia, localized prostate cancer, advanced
metastatic prostate cancer).
Measurements were made on 9984 genes for 101 individuals, of whom 79 have
cancers and 22 do not. Before analyzing the data, we filtered out genes that had
a sample variation less than 0.05 across all samples. This left a total of G ≡ 6253
genes available for analysis.
First, a q-value analysis (Storey [28]) was done using the unpooled two-sample
t-test; this is reported in Figure 1. For this analysis, we assumed a theoretical null
distribution of N(0, 1) for each t-statistic. One point of note from the plot is the
estimate of pi0, the fraction of null hypotheses estimated to be true, is 0.49. As
a result, we are finding a large proportion of genes to be differentially expressed.
Fig 1. Results of the q-value analysis (Storey [28]) for prostate cancer gene expression data.
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Table 2
Results of sensitivity analyses for gene expression data
γ (µ1 − µ0) pˆi0 Number q-values ≤0.05
0 0 0.49 2099
1.5 0.01 0.86 1762
0.1 0.47 613
0.3 0.05 6227
0.5 0.01 6253
1 0.006 6253
0.1 0.01 0.49 2415
0.1 0.78 1902
0.3 0.86 1466
0.5 0.80 1154
1 0.69 586
As argued by Ghosh and Chinnaiyan [17], there is a variety of confounders that
might cause the apparent observed difference between the cancer and noncancer
samples. The implication is that the standard normal distribution might not be the
correct reference null distribution to use. We tried adjustments to the t-statistic
based on the sensitivity analysis approach. First, we assumed a confounder that
was continuous and tried various values of (γ, µ1, µ0) to obtain estimates of pi0 and
the q-values. Note that what matters is the difference in means µ1 − µ0, so we
considered changes of 0.01, 0.1, 0.3, 0.5 and 1. We have aggregated the sensitivity
results into Table 2. What we find is that the estimate of pi0 is extremely sensitive
to confounders. Interestingly, as the product of γ and (µ1 − µ0) decreases, we find
that the estimate of the proportion of true null hypotheses increases, which leads to
a decrease in the number of genes being called significant if we use a cutoff of 0.05,
say. However, we also see that there is no simple relationship between the amount of
confounding and the estimate of pi0. The estimate of number of genes being called
significant is also sensitive to the estimate of pi0. For example, there is very little
difference in the estimates of pi0 for the unadjusted and (γ, µ1 − µ0) = (0.1, 0.01)
situation, yet we are calling approximately four hundred more genes significant in
the second scenario. This emphasizes the need to have good estimates of pi0.
Next, we utilized the Efron [11] method for estimating the local false discovery
rates; the results are presented in Figure 2. Again, this procedure corresponds to
a data-driven adjustment to null hypotheses for confounding. Now note that the
estimate of pi0 from the Efron [11] procedure is 0.88, almost 80% larger than the
estimate using the method of Storey [28]. This fits into our intuition that adjusting
for confounding should decrease the number of significant genes. We next calculated
the double-shrinkage estimators for the t-statistics using the method in Section 3.1.
We then combined an FDR-thresholding procedure with the inference procedures
described in the paper. This was done in the following manner. We applied the
q-value procedure of Storey [28] and selected the genes with the twenty smallest q-
values. We reported the effects and associated 95% confidence intervals in Table 3.
Note that the 95% CIs should be conservative in that we have ignored the selection
process (i.e. taken the twenty genes with the smallest q-values).
6. Discussion
In this article, we have addressed the issue of multiple testing procedures in the
presence of confounding. First, we sought to unify proposals from the statistical
and genetics literature on the problem. Doing so clarifies and provides a stronger
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Fig 2. Results of the t-test statistics from the prostate cancer gene expression data using the local
false discovery rate estimation procedure of Efron [11].
Table 3
Results for top 20 genes for prostate cancer gene expression data
Gene name Estimator S βˆ 95% CI
Transforming growth factor, beta 1 6.99 0.30 (0.09, 0.52)
Fer-1-like 3, myoferlin (C. elegans) 8.36 0.55 (0.14, 0.93)
O-linked N-acetylglucosamine transferase −9.11 −0.51 (−0.88,−0.18)
Human calmodulin-I (CALM1) mRNA 6.87 0.56 (0.17, 0.98)
Hepsin (transmembrane protease, serine 1) −6.89 −0.95 (−1.62,−0.30)
Caveolin 2 7.44 0.53 (0.16, 0.85)
Ras homolog gene family, member B 6.7 1.41 (0.42, 2.40)
Zinc finger protein 36, C3H type-like 1 6.76 0.52 (0.16, 0.87)
Hepatic leukemia factor 6.72 0.46 (0.11, 0.78)
Phosphatidic acid phosphatase type 2B 6.59 0.34 (0.08, 0.60)
Multiple endocrine neoplasia I −6.51 −0.31 (−0.54,−0.08)
Endothelin receptor type A 6.47 0.51 (0.12, 0.92)
Transforming growth factor, beta receptor III 6.38 0.54 (0.10, 0.98)
Growth factor receptor-bound protein 2 −6.31 −0.42 (−0.77,−0.12)
Hermansky-Pudlak syndrome 1 6.32 0.34 (0.07, 0.58)
Dickkopf homolog 3 (Xenopus laevis) 6.29 0.34 (0.09, 0.61)
Phosphatidic acid phosphatase type 2B 6.24 0.32 (0.06, 0.57)
Tissue inhibitor of metalloproteinase 3 6.2 0.55 (0.12, 1.00)
Hypothetical protein hCLA-iso −6.13 −0.38 (−0.70,−0.09)
Zinc finger protein 36, C3H type-like 2 6.08 0.34 (0.08, 0.62)
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justification for preferring the empirical null distribution that Efron [11] has recently
advocated. It is also clear from the discussion that what the methods of Devlin
and Roeder [10] and Pritchard and Rosenberg [23] provide are adjustments to the
theoretical null, using supplemental data and under various assumptions on the
nature of confounding and its effects on location and scale parameters.
Second, we have proposed two analytical approaches. The first is a sensitivity
analysis approach using a methodology described by Lin et al. [19], which is then
plugged into standard FDR methodology. As shown in the article, this can be
viewed as a mean-shift adjustment to the theoretical null. The second procedure
in the article we pursue is one using Empirical Bayes methodology. This involves
utilizing the mixture model for hypothesis testing in the presence of confounding
proposed by Efron [11] and constructing James-Stein estimators of the test statistic
that shrinkage towards each target (that specified under the null and that under
the alternative) with data-dependent weights. What is novel here is that the mean
value of the distribution of the test statistic under the null is also estimated as part
of the procedure. This leads to calibration of the test statistics under the empirical
null hypothesis (Efron [11]) rather than the theoretical null hypothesis. We also
develop confidence intervals in the multiple testing setting, which has not been
discussed very much in the literature, with the major exception being the work on
FDR-controlling confidence intervals by Benjamini and Yekutieli [5].
The methodology proposed here is fairly general. The sensitivity analysis regres-
sion models considered here are a subset of those considered by Lin et al. [19];
the methodology proposed here could apply more generally to censored outcomes
through proportional hazards regression models and count responses using Pois-
son regression models. The double shrinkage estimation methodology in Section 4
requires having Wald-type estimators.
While there have been Empirical Bayes methods for multiple testing proposed
in the literature (Efron et al. [12], Datta and Datta [9] and Ghosh [16]), most of
this work has focused on hypothesis testing and selection of hypotheses. While this
is useful in screening problems, it might also be of interest to report estimated
effects and confidence intervals corresponding to the rejected null hypotheses. A
major potential advantage of Empirical Bayes (and more generally, fully Bayesian)
methods in this setting is that parameter estimates and confidence intervals will
be unaffected by the selection of which hypotheses to reject, provided the testing
procedure is Bayesian. This is an area that is currently under investigation.
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